Abiopharma

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

(90% Positive) Nurix Therapeutics Inc (NRIX) Files Form 8-K

(90% Positive) Acumen Pharmaceuticals Inc (ABOS) Announces Clinical Development Update

(99% Positive) Clearpoint Neuro Inc (CLPT) Announces Clinical Development Update

(90% Positive) Prime Medicine Inc (PRME) Files Form 8-K

(99% Neutral) Myriad Genetics Inc (MYGN) Announces Business Combination

(99% Positive) Outset Medical Inc. (OM) Reports Q1 2026 Financial Results

Vicarious Surgical Inc. - Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

Schrödinger, Inc. - Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

(90% Positive) Microbot Medical Inc (MBOT) Provides Update on strive for peripheral endovascular procedures

ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

Allurion - Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Mirum Pharma - Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

(85% Positive) Sonoma Pharmaceuticals Inc. (SNOA) Files Form 8-K